We’re John, Will, and Trent and we’re here to give our listeners what they want. Here is all the basketball talk you need.
…
continue reading
Author interviews, Reading Short Stories & Behind the scenes of making fiction.
…
continue reading
The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. SUBSCRIBE to our new newsletter at www.bioprocessonline.com/bob. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, and regulatory challenges you’ll face as you navigate your company from an idea to success in the clinic. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business of Biotech is p ...
…
continue reading
Here businesses, artists and creators can talk about issues important to building brands, fans and exposure. We are not solely music as we touch on development and relatable subjects that give informative content to all cultures of business for community growth. Our show features a new topic weekly. For INTERVIEWS: email JANNYSHMANNY at host@thecomfortlevel.com Become a paid subscriber for free promo opportunities https://podcasters.spotify.com/pod/show/thecomfortlevelpodcast/subscribe
…
continue reading
1
Embracing Biotech Chaos With Memo's Erik van den Berg
54:05
54:05
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
54:05
We love to hear from our listeners. Send us a message. Erik van den Berg is CEO and board member at Memo Therapeutics, and he's a student of biotech chaos. In fact, he's been embracing it with intention for the past 30 years. On this episode of the Business of Biotech, he walks us through the management of that chaos in specific detail. Navigating …
…
continue reading
1
Pivoting To RNA With Circio's Dr. Erik Digman Wiklund
1:04:47
1:04:47
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
1:04:47
We love to hear from our listeners. Send us a message. This week, it’s another “Business of Biotech-meets-Business-of-RNA” takeover with Circio CEO Erik Digman Wiklund, Ph.D. and guest co-host Anna Rose Welch of Advancing RNA. While Circio’s legacy is in cancer immunology (it still boasts a cancer vaccine candidate targeting KRAS driver mutations),…
…
continue reading
1
mRNA Upstarts With Radar Therapeutics' Sophia Lugo and Eerik Kaseniit, Ph.D.
1:03:07
1:03:07
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
1:03:07
We love to hear from our listeners. Send us a message. Guest co-host Anna Rose Welch of Advancing RNA fame joins us on this week’s Business of Biotech podcast for a conversation with the leaders of RNA upstart Radar Therapeutics. The company’s co-founders, Eerik Kaseniit, Ph.D. (CSO & President) and Sophia Lugo (CEO), are making waves in the mRNA t…
…
continue reading
1
Steering Through Setbacks with AVEO Oncology's Michael Bailey
58:06
58:06
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
58:06
We love to hear from our listeners. Send us a message. For all the drug commercialization successes he's played a leading hand in during his tenures at GSK, Genentech, and ImClone—Androderm, Augmentin, necitumumab, and Erbitux among them—Michael Bailey concedes that he's likely better known for his failures. After hearing his stories on this episod…
…
continue reading
1
Leading From Within with ISCT & Kiji's Miguel Forte, M.D.
59:37
59:37
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
59:37
We love to hear from our listeners. Send us a message. He's been a big pharma executive. He's a multi-time biotech founder and current biotech CEO. He was once a regulator. He's a physician. He serves on multiple boards. And as of this summer, he's president of one of the most influential global organizations dedicated to the advance of cell and ge…
…
continue reading
1
The Allogeneic Future with Poseida's Kristin Yarema, Ph.D.
1:04:44
1:04:44
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
1:04:44
We love to hear from our listeners. Send us a message. Kristin Yarema, Ph.D. thinks the progress of CAR T therapeutics is allogeneic. In fact, she says CAR T-cell therapies have to become a one-to-many proposition, if their early autologous success can possibly live up to the promise of offering widespread accessibility to life-saving treatments. D…
…
continue reading
1
Expanding The Proteome with ProFound's John Lepore, M.D.
56:38
56:38
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
56:38
We love to hear from our listeners. Send us a message. Flagship Pioneering’s ProFound Therapeutics is on to something, and it could be something big. It began with a simple question: What if more RNAs were being translated into proteins? Answering that question took ProFound deep into the translatome, where it’s now studying the full compendium of …
…
continue reading
1
From The Bench To The Boardroom with ImmunityBio's Enrique Diloné
1:06:39
1:06:39
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
1:06:39
We love to hear from our listeners. Send us a message. While organic chemistry lectures caused many of his peers at NYU to wring their hands, gnash their teeth, and question life choices, then-19-year-old Enrique Diloné ate those classes for lunch. They inspired him to earn a Seton Hall Ph.D. in chemistry, and to go to work as a big bio research sc…
…
continue reading
1
First AI Antibody In Humans with Aulos' Aron Knickerbocker
1:08:52
1:08:52
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
1:08:52
We love to hear from our listeners. Send us a message. Data drives decision-making at Aulos Bioscience. It's also driven the career trajectory of its CEO. On this week's episode of the Business of Biotech podcast, we get an introspective walk through Aron Kinickerbocker's strategically-orchestrated career path, from his early days in the labs at Br…
…
continue reading
1
Drug Delivery Differentiators with Syncromune's Eamonn Hobbs
1:12:31
1:12:31
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
1:12:31
We love to hear from our listeners. Send us a message. Syncromune's Sync-T solid tumor therapeutic platform is, in a word, complex. The company's three phase 1 programs combine T-cell science with a proprietary drug delivery device to target solid tumors, specifically metastatic breast, non-small-cell lung, and castrate-resistant prostate cancers. …
…
continue reading
1
Topical Ocular Biologics with Claris Bio's Clarke Atwell
58:06
58:06
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
58:06
We love to hear from our listeners. Send us a message. Built on the back of hepatocyte growth factor discoveries by Harvard Drs. Reza Dana and Sunil Chauhan, ClarisBio is rewriting the ophthalmology rulebook. CEO Clark Atwell acknowledges that it's not the first to bring topically-administered biologic therapies to the front of the eye, but if succ…
…
continue reading
1
C&G Regulatory Guidance with Lineage Therapeutics' Brian Culley
1:04:02
1:04:02
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
1:04:02
We love to hear from our listeners. Send us a message. When we last caught up with Brian Culley, CEO at Lineage Cell Therapeutics, it was January, 2021. A pandemic was raging. His company was moving mountains to keep its OpRegen dry AMD clinical trial together, and did so despite lockdowns that kept a largely aged patient population from setting fo…
…
continue reading
1
True DEI Value in Biopharma with Arcellx's Rami Elghandour
1:04:08
1:04:08
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
1:04:08
We love to hear from our listeners. Send us a message. The cell therapy company Arcellx has, by any and every measure, been outperforming its peers. Its stock has rallied on the back of the strong performance of its multiple myeloma candidate, and the promise of its AML, MDS, and solid tumor pipelines is attracting the kind of interest it takes to …
…
continue reading
1
Mission-Driven Dementia Funding with DDF's Jonathan Behr
55:46
55:46
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
55:46
We love to hear from our listeners. Send us a message. If there's anyone qualified to analyze an early-stage therapeutic technology and place bets with other people's money, it's scientist-turned-venture capitalist Jonathan Behr, Ph.D. He built a distinguished venture capital career on the back of an MIT Ph.D. in biological engineering, having co-f…
…
continue reading
1
ADCs Ignited with Daiichi Sankyo Inc.'s Ken Keller
1:04:06
1:04:06
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
1:04:06
We love to hear from our listeners. Send us a message. Just a few years ago, Daiichi Sankyo wasn't considered a player in the oncology therapeutics space, and it certainly wasn't a player in ADCs. But then, just a few years ago, who was? Fast forward to 2023, and we see an ADC arena that drove nearly $100 billion in M&A, licensing, and partnership …
…
continue reading
1
Accelerating ADCs with Mythic Therapeutics' Brian Fiske, Ph.D.
56:38
56:38
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
56:38
We love to hear from our listeners. Send us a message. Mythic Therapeutics Chief Scientific Officer and co-founder Brian Fiske, Ph.D. broke some unwritten protocol with his rapid and multifaceted transition from academia to industry. He calls his many, and sometimes concurrent, early experiences as an MIT Ph.D. student, a Flagship Ventures Fellow, …
…
continue reading
1
WHERE I’M FROM “PAST IZ HISTORY” by SUPREEM DA REZAREKTA’ (JEMAL CARTER)
6:30:20
6:30:20
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
6:30:20
JEMAL CARTER is a prominent HipHop Artist/Actor/Author hailing from Philadelphia. JanyShmanny reads aloud the very first autobiography written by SUPREEM DA REZAREKTA’ and live appearance reading/insights with the author.
…
continue reading
1
The Anti-CDMO with CTMC's Jason Bock, Ph.D. and KSQ's Thomas Leitch
57:35
57:35
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
57:35
We love to hear from our listeners. Send us a message. This isn't your typical drug sponsor + CDMO story. In fact, CTMC's Jason Bock, Ph.D. says you shouldn't even classify his company a CDMO. He's not wrong. While some of the company's services aren't dissimilar from those offered by a contract developer, CTMC began with a more fundamental mission…
…
continue reading
1
A New Prescription For PBMs with Allan Shaw
40:13
40:13
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
40:13
We love to hear from our listeners. Send us a message. Back by popular demand, biopharma industry opinionator extraordinaire Allan Shaw rejoins the Business of Biotech to expose the murky role Pharmacy Benefit Managers (PBMs) play in the last, costly mile of the drug distribution supply chain. Allan pulls no punches in his criticism of the current …
…
continue reading
1
New Apps For AI in mRNA With Anima Biotech's Yochi Slonim
59:10
59:10
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
59:10
We love to hear from our listeners. Send us a message. From San Francisco’s Silicon Valley to Tel Aviv’s Silicon Wadi, software business entrepreneur Yochi Slonim made a name for himself in global tech hubs around the globe. Notably, he was co-founder of billion-dollar Mercury Interactive, which HP acquired for $4.5 billion, and previous to that a …
…
continue reading
1
CARLINA STACKS #BARZNBANGERZ ARTIST SHOW
1:54:41
1:54:41
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
1:54:41
Calina Stacks creator of "SEXY TRAP" an upcoming female emcee hauling from Camden, NJ. (I do not own the rights to the music)
…
continue reading
1
Circular RNA with Orna Therapeutics' Tom Barnes, Ph.D. and Advancing RNA's Anna Rose Welch
59:11
59:11
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
59:11
We love to hear from our listeners. Send us a message. As if Orna Therapeutics' CEO Thomas Barnes, CEO isn't a enough to draw you in to the Business of Biotech, we teamed up with Advancing RNA Editorial & Community Director Anna Rose Welch to co-host this week's episode. Together, Anna Rose and I press Dr. Barnes on his transition from academia to …
…
continue reading
1
Physician + Biotech Builder with Tome Biosciences' Rahul Kakkar, M.D.
1:01:30
1:01:30
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
1:01:30
We love to hear from our listeners. Send us a message. Novel technologies aren’t interesting to Rahul Kakkar, M.D. unless they help patients. Sounds rational, but it’s actually a unique perspective in a platform-crazed biotech industry. Dr. Kakkar’s worldview is shaped by his work as a physician—work he continues at Brigham and Women’s Hospital eve…
…
continue reading
1
Commercial Readiness with ImmunityBio's Bobby Reddy, M.D.
56:54
56:54
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
56:54
We love to hear from our listeners. Send us a message. This episode of the Business of Biotech begins with a personal story about my dad and the standard of care in bladder cancer, before shifting to the work that Dr. Bobby Reddy and his team at ImmunityBio are doing to change that standard of care. They're painfully close. Dr. Reddy, Chief Medical…
…
continue reading
1
JOSELYN LUGO, LICENSED ESTHETICIAN
1:43:52
1:43:52
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
1:43:52
#THIRTYTHURSDAY NEWS STORIES #TOPIC:BRAND PROMOTION/BRAND LOYALTY #GETFEATURED GUEST: JOSELYN LUGO LICENSED ESTHETICIAN
…
continue reading
1
Precision Drug Delivery with Ampersand Biomedicines' Jason Gardner, D.Phil.
49:47
49:47
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
49:47
We love to hear from our listeners. Send us a message. Ampersand Biomedicines CEO Jason Gardner, D.Phil. first took the leap from a global pharmaceutical giant to a startup at the forefront of transplant medicine innovation. Since that time, he's seen most of the ups and the downs that come with biotech leadership, and in his latest venture with th…
…
continue reading
1
Funding Alzheimer's Tx Dev with ADDF's Karen Harris
40:16
40:16
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
40:16
We love to hear from our listeners. Send us a message. We've really been looking forward to dropping this episode with Karen Harris, Chief Financial Officer and Head of Mission-Related Investing at the Alzheimer's Drug Discovery Foundation. While the markets have warmed a bit since we recorded this episode, Karen's thoughtful perspective on the som…
…
continue reading
1
The AI Impact with Generate:Biomedicines' Mike Nally
1:13:54
1:13:54
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
1:13:54
We love to hear from our listeners. Send us a message. Few drug discovery and development concepts are as hyped, and as such, draw as much polarity from drug developers, as machine learning and artifical intelligence. One company on the bullish end of the spectrum is Flagship Pioneering's Generate Biomedicines, which bills itself at the "intersecti…
…
continue reading
1
Strategic Deals with CinRx's Gavin Samuels, M.D.
47:52
47:52
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
47:52
We love to hear from our listeners. Send us a message. Gavin Samuels, M.D. found his work as an intensive care physician boring. After earning his M.D., he did that for a few years before moving into intensive care management roles. It wasn't until he left the hospital and entered biopharma that he found his footing, cutting his teeth in business d…
…
continue reading
1
Serial Success With Triumvira's Rob Williamson
31:32
31:32
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
31:32
We love to hear from our listeners. Send us a message. Rob Williamson's mind and hands have shaped more than 20 biotech startups, leading some to IPO and landing others firmly in Big Bio through acquisition by companies like Merck. Hanging around as many successful exits as Williamson has seen, one might become expert via osmosis. But Williamson is…
…
continue reading
1
"DJX" THE DEAR JOHN EXPERIENCE
49:22
49:22
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
49:22
DEAR JOHN TALKS ABOUT HIS UPCOMING ALBUM "THE HEART SURGEON" DEDICATED TO SUICIDE PREVENTION AWARENESS.
…
continue reading
1
WOMEN'S HISTORY MONTH
2:03:56
2:03:56
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
2:03:56
March is International Women's History Month Since 1911 a global celebration honor and remember women who now and throughout history have embodied the importance of equality, inclusion and fairness. Today, The Comfort Level Podcast commemorates Mrs, Dayna Hicks, of ENVISIONSUCCESS ORG, a true Heroine of today (We do not own the rights to the music)…
…
continue reading
1
The Innovator's Dilemma with Lumen Bioscience's Brian Finrow, J.D.
50:43
50:43
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
50:43
We love to hear from our listeners. Send us a message. In biotech, when "one of these things doesn't look like the other one," it can be a blessing or a curse. On one hand, scientific novelty is praised and rewarded. On the other, unfamiliarity breeds skepticism from the investment community. Brian Finrow, J.D. embraces that reality and the challen…
…
continue reading
1
#BARZNBANGERZ TOP 10 ARTIST CONTEST/PROMO WEEK #3
1:24:40
1:24:40
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
1:24:40
WEEK #3 OF THE COMFORT LEVEL PODCAST'S #BARZNBANGERZ ARTIST CONTEST/PROMO TO BUILD VIEWS ON YOUTUBE CHANNELS TO PREPARE FOR MONETIZATION. WINNER WAS MOODY144000 (WE DO NOT OWN THE RIGHTS TO THE MUSIC)
…
continue reading
1
Precision Radiopharmaceuticals with Ratio's Jack Hoppin, Ph.D.
40:38
40:38
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
40:38
We love to hear from our listeners. Send us a message. Multimodal approaches to the delivery of radiologically active compounds have created a fertile environment to for players in the space to put on a precision medicine clinic, so to speak. What’s more, Radiopharmaceuticals create a unique business opportunity given the closely-related and necess…
…
continue reading
1
#BARZNBANGERZ TOP 10 CONTEST/ WINNER INTERVIEW WITH "ZEVENSHOTS"
1:33:53
1:33:53
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
1:33:53
1st Round winner ZEVENSHOTS interview. Most votes for his #youtube track "Playoffs" (We do not own the rights to the music)
…
continue reading
1
Managing Mergers With Sail Biomedicines' Guillaume Pfefer, Ph.D.
51:07
51:07
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
51:07
We love to hear from our listeners. Send us a message. While you might be aware that Sail Biomedicines was just formed up in Q4 of last year, the product of Flagship Pioneering’s decision to merge Senda Biosciences and Laronde, two of its programmable medicine platform companies. What you likely haven’t heard is the inside story on how the merger w…
…
continue reading
TOP 10 ARTIST CONTEST/REVIEW(We do not own the rights to the music)10 Artists submit tracks..engagers comments count as votes as we review the track! 2 prize winners every week! host@thecomfortlevel.com to submit
…
continue reading
1
Reprogramming Human Cells With bit.bio's Mark Kotter, M.D.
45:51
45:51
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
45:51
We love to hear from our listeners. Send us a message. The concept of programmable biology is fueling a new breed of biotech, one that requires the marriage of computational and traditional science (and both computational and traditional scientists) on the entire journey from discovery to commercial. Bit.bio is exemplary of this new breed. Its CEO,…
…
continue reading
1
Inhalable mRNA with Ethris' Carsten Rudolph, Ph.D.
46:59
46:59
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
46:59
We love to hear from our listeners. Send us a message. Without doubt, the grand and collaborative experiment that was the mRNA COVID vaccine contributed mightily to the pandemic response and continues to save lives untold. It also demonstrated the collective power of public/private partnership in biopharma. Having acknowledged that, no first iterat…
…
continue reading
1
PROFESSIONAL A$$HOLE RETURNS #THIRSTYTHURSDAY
1:59:19
1:59:19
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
1:59:19
UPCOMING #TIKTOK SENSATION @PROFESSIONAL_ASSHOLE RETURNS TO THE SHOW. *DISCLAIMER THE VIEWS AND STATEMENTS MADE BY OUR GUESTS OR VIEWERS ARE NOT NECESSARILY THE VIEWS OF THE COMFORT LEVEL PODCAST. **(WE DO NOT OWN THE RIGHTS TO THE MUSIC) Music Credits Firenation Flamez ft Paper$ Pawman ft FG Laflare…
…
continue reading
1
IS THE LIFE YOU LIVE BY DESIGN?
1:33:12
1:33:12
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
1:33:12
PHONE INTERVIEW WITH AUTHOR RUSTIE MACDONALD WWW.RUSTIE.COM
…
continue reading
1
Biotech Is Back with Allan Shaw
51:02
51:02
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
51:02
We love to hear from our listeners. Send us a message. The Business of Biotech took a trip to San Francisco for the JP Morgan Healthcare Conference, that most target-richest of environments for those of us who like talking shop with biotech builders. The results of that trip will feed the next several weeks of Business of Biotech podcast programmin…
…
continue reading
1
#BARZNBANGERZ "THE ARTIST OF WORDS" SHALEENA MORRELL
1:36:04
1:36:04
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
1:36:04
SHALEENA MORRELL OWNER OF WWW.VINTAGECULTURECOLLECTION.COM HAS AMZING TALENTS AS AN ENTREPRENEUR, POET, PLAYWRITER AND AUTHOR.
…
continue reading
1
Multimodal R&D Management with Incyte's Jim Lee, M.D., Ph.D.
50:31
50:31
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
50:31
We love to hear from our listeners. Send us a message. Success at multimodal, multi-indication, deep-pipelined Incyte—where commercial operations are as familiar as pre-discovery activity is—begins at the earliest opportunity to achieve research and discovery efficiencies. The company’s a bit larger than those we typically cover on the Business of …
…
continue reading
1
WHO?MAG"S ROB SCHWARTZ..CO FOUNDER/CMO/PRESIDENT OF MUSIC AT #ACX1STUDIOS ATLANTIC CITY BOARDWALK, NJ
1:47:02
1:47:02
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
1:47:02
WHO?MAG"S ROB SCHWARTZ..CO FOUNDER/CMO/PRESIDENT OF MUSIC AT #ACX1STUDIOS ATLANTIC CITY BOARDWALK, NJ TALKS ABOUT DISTRIBUTION AND NEWEST VENTURE ...ACX1STUDIOS MULTIMEDIA/FILM COMPLEX.
…
continue reading
1
Building A Biotech Hub with Intellia Therapeutics' John Leonard, M.D.
55:03
55:03
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
55:03
We love to hear from our listeners. Send us a message. We spend a lot of time talking with our guests about building biotech companies. That’s true of this episode too, but today we’re taking a step further with John Leonard, M.D., longtime CEO at Intellia Therapeutics. In addition to how he’s built late-clinical stage Intellia, Dr. Leonard shares …
…
continue reading
#GETFEATURED GUEST "PROFESSIONAL ASSHOLE" UPCOMING OPINIONATED #TIKTOK SENSATION AND MUSIC ARTIST.
…
continue reading
1
Art Of The Pivot with Elevation Oncology's Joe Ferra
49:56
49:56
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
49:56
We love to hear from our listeners. Send us a message. Relatively new CEO Joseph Ferra has orchestrated some pretty significant change at Elevation Oncology in the two(ish) years since the Business of Biotech last hosted the company. In that short time, Ferra advance from CFO to CEO, a move that aligned very closely with the company's difficult dec…
…
continue reading
1
ENVISION SUCCESS...DREAM WITH YOUR EYES OPEN .. MS DAYNA HICKS
1:59:41
1:59:41
Lire Plus Tard
Lire Plus Tard
Des listes
J'aime
Aimé
1:59:41
MS. DAYNA HICKS CEO/FOUNDER F ENVISION SUCCESS TRANSITIONAL HOUSING PROGRAM FOR YOUTHS LEAVING FOSTER CARE. For more information contact info@envisionsuccess.orgWWW.ENVISIONSUCCESS.ORG
…
continue reading